13.05.2022 - UroGen Pharma Ltd. (Nasdaq: URGN) today highlighted four presentations of interest featuring data on JELMYTO (mitomycin) for pyelocalyceal solution for patients with low-grade upper tract urothelial cancer (LG-UTUC) and investigational agent UGN-102 . Seite 1